Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
Functional Relapses in Pediatric Multiple Sclerosis.
The role of pro- and anti-inflammatory cytokines in the pathogenesis of spontaneous canine CNS diseases.
Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
The Emerging Role of MitomiRs in the Pathophysiology of Human Disease.
Estrogen treatment of experimental autoimmune encephalomyelitis requires E2 receptor positive B cells that upregulate PD-1 on CD4(+) Foxp3(+) Treg cells.
Dendritic cells as therapeutic targets in neuroinflammation.
Mitochondrial dysfunctions in 7-ketocholesterol-treated 158N oligodendrocytes without or with α-tocopherol: Impacts on the cellular profil of tricarboxylic cycle-associated organic acids, long chain saturated and unsaturated fatty acids, oxysterols, chol
More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO).
Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience.
Optic neuritis as first clinical manifestations the multiple sclerosis.
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.
Comparison of the affective symptomatology between liver transplant recipients and patients with multiple sclerosis considering their functional impairment.
Progress and Roadblocks Along the Pathway to Multiple Sclerosis Treatment.
Effect of ether glycerol lipids on interleukin-1β release and experimental autoimmune encephalomyelitis.
Clinical and imaging findings in three patients with advanced inflammatory demyelinating polyradiculoneuropathy associated with nerve root hypertrophy.
Examining vascular remodeling in the hypoxic central nervous system.
In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195.
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica.
Role of orexin-A in experimental autoimmune encephalomyelitis.
Modulation of C-nociceptive Activities by Inputs from Myelinated Fibers.
Mosaic Subventricular Origins of Forebrain Oligodendrogenesis.
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis.
Pages
« first
‹ previous
…
662
663
664
665
666
667
668
669
670
…
next ›
last »